Hepatic steatosis in HIV‐HCV coinfected patients in France: comparison with HCV monoinfected patients matched for body mass index and HCV genotype

Castéra, Laurent; Loko, Marc-Arthur; Bail, Brigitte Le; Coffie, Patrick A.; Lédinghen, Victor de; Trimoulet, Pascale; Winnock, María; Dabis, François; Néau, Didier

doi:10.1111/j.1365-2036.2007.03533.x

Cited by 42 publications

(68 citation statements)

References 43 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Twelve studies were included [19][20][21][22][23][24][25][26][27][28][29][30] addressing a total of 1,989 HIV/HCV-coinfected patients. In four of these studies 20,24,25,28 data regarding HCV-monoinfected patients were presented separately, with a total of 1,540 patients.…”

Section: Resultsmentioning

confidence: 99%

“…In four of these studies 20,24,25,28 data regarding HCV-monoinfected patients were presented separately, with a total of 1,540 patients. Three studies had a retrospective recruitment 21,22,25 ; the remaining were prospective. HS was always evaluated by liver biopsy.…”

Section: Resultsmentioning

confidence: 99%

“…All of them required patients to be HCV treatment-naives and negative for hepatitis B surface antigen. Except for significant alcohol consumption, greater than 40-50 g per day, which was an exclusion criterion in only five studies, [23][24][25]27,28 other causes of liver disease were systematically excluded. Liver biopsies with less than 10 mm length were considered as an exclusion criterion in just two studies.…”

Section: Resultsmentioning

confidence: 99%

“…Liver biopsies with less than 10 mm length were considered as an exclusion criterion in just two studies. 25,26 Decompensated liver cirrhosis was a transversal exclusion criterion.…”

Section: Resultsmentioning

confidence: 99%

“…33 Two studies 25,26 used the chronic hepatitis C validated METAVIR classification system, 34 in which steatosis is considered mild if present in 1%-10% of the hepatocytes, moderate in 11%-30%, and severe when in more than 30%. Necroinflammation and fibrosis were graded or staged by METAVIR 20,21,23,25,26 or Ishak classifications. 35 Steatosis Prevalence.…”

Section: Resultsmentioning

confidence: 99%

See 4 more Smart Citations

Hepatic steatosis in patients coinfected with human immunodeficiency virus/hepatitis C virus: A meta-analysis of the risk factors

2010

View full text Add to dashboard Cite

Hepatic steatosis (HS) is frequent in patients with hepatitis C virus (HCV) infection, occurring in 40%-80%, associating with metabolic and virus-related factors, namely, genotype 3 and viral load. Human immunodeficiency virus (HIV) infection and antiretroviral treatment seem to be risk factors for HS. Several studies addressed this issue in coinfected patients, with discrepant results. A meta-analysis was performed on the HS risk factors in coinfected patients. Eligible studies were identified through structured keywords including coinfection, HCV, HIV, and steatosis in relevant databases including PubMed. Pooled odds ratios (ORs) and confidence limits (CIs) were obtained with the random-effects model and the DerSimonian-Laird method. Twelve studies, including 1,989 coinfected patients, were selected. Twenty percent were infected with HCV genotype 3. The overall prevalence of HS was 50.8% (23%-72%). Four studies also included 1,540 HCV monoinfected patients, not showing an increased risk for HS in coinfected patients (OR 1.61, 95% CI 0.84-3.10, P 5 0.151). In coinfected patients, HS was associated with higher body mass index (OR 1.13, 95% CI 1.07-1.19, P < 0.001), diabetes mellitus (OR 2.32, 95% CI 1.32-4.07, P 5 0.003), elevated alanine aminotransferase levels (OR 1.28, 95% CI 1.02-1.61, P 5 0.035), necroinflammatory activity (OR 1.72, 95% CI 1.11-2.67, P 5 0.016), and fibrosis (OR 1.67, 95% CI 1.20-2.34, P 5 0.003). No associations were found between HS and gender, other metabolic factors (dyslipidemia, glucose, metabolic syndrome), HCV-related factors (genotype, viral load), or HIV-related factors (viral load, CD4 count, antiretroviral therapy, and class of medication). Conclusion: In coinfected patients, HS does not seem to be more frequent than in HCV monoinfected patients and is mostly associated with metabolic factors, such as increased weight, diabetes mellitus, and more severe liver disease. The fact that no associations with HCV factors were found may be due to the small percentage of genotype 3-infected patients. (HEPATOLOGY 2010;52:71-78)

show abstract

Section: Resultsmentioning

confidence: 99%

Section: Resultsmentioning

confidence: 99%

Section: Resultsmentioning

confidence: 99%

“…Liver biopsies with less than 10 mm length were considered as an exclusion criterion in just two studies. 25,26 Decompensated liver cirrhosis was a transversal exclusion criterion.…”

Section: Resultsmentioning

confidence: 99%

Section: Resultsmentioning

confidence: 99%

See 3 more Smart Citations

Hepatic steatosis in patients coinfected with human immunodeficiency virus/hepatitis C virus: A meta-analysis of the risk factors

2010

View full text Add to dashboard Cite

show abstract

Hepatitis C Virus Infection and Coinfection With Human Immunodeficiency Virus

Hadigan

Kottilil²

2011

JAMA

View full text Add to dashboard Cite

Hepatitis C virus (HCV) and human immunodeficiency virus (HIV) both emerged in the second half of the 20th century, and chronic infection with these agents is among the greatest challenges facing health care in the United States and worldwide. Despite tremendous advances in treatment and management of HIV and HCV, individuals with HIV/HCV coinfection experience a more complicated disease course and treatment. Recognition of the important role that host factors, such as IL28B genotype, have in response to HCV therapy and the emergence of new effective therapies for HCV are actively reshaping the standard of care. These advances may translate into more effective treatment and management of patients with chronic HCV and HIV coinfection in the years ahead.

show abstract

Hepatic steatosis and steatohepatitis in human immunodeficiency virus/hepatitis C virus-coinfected patients

et al. 2012

View full text Add to dashboard Cite

Hepatic steatosis (HS) is frequent in human immunodeficiency virus (HIV)-and hepatitis C virus (HCV)-coinfected patients. Antiretroviral therapy (ART) and metabolic alterations could induce HS. However, a protective effect of ART has been reported in a paired biopsy study. Thus, our aim was to examine the changes and predictors of HS progression among HIV/HCV-coinfected patients with sequential biopsies. We also evaluated the rates of steatohepatitis and factors associated thereof. HIV-infected patients with detectable serum HCV RNA, who underwent two biopsies, separated at least by 1 year, were included in this retrospective study. HS progression was defined as increase in one or more HS grades. The median (interquartile range) time between biopsies was 3.3 (2.0-5.2) years. Among 146 individuals, HS at baseline was observed in 86 (60%) patients and in 113 (77%) in the follow-up biopsy (P < 0.001). Progression of HS was observed in 60 (40%) patients. 01-5.7]; P 5 0.047). Conclusions: HS progresses frequently and regression is rarely observed in HIV/HCV-coinfected patients, including in those on ART. Cumulative exposure to dideoxynucleoside analogs and increases in FPG are related with HS progression. Stetatohepatitis is frequently observed in these patients and is linked to fibrosis progression. (HEPATOLOGY 2012;56:1261-1270 H epatic steatosis (HS) is a common condition in hepatitis C virus (HCV)-infected patients with human immunodeficiency virus (HIV) coinfection. Previous cross-sectional studies have reported on frequencies of HS between 30% and 70%. [1][2][3][4][5][6][7][8][9][10][11][12] Besides its prevalence, the main clinical

show abstract

Hepatic steatosis in HIV‐HCV coinfected patients in France: comparison with HCV monoinfected patients matched for body mass index and HCV genotype

Abstract: SUMMARY BackgroundSignificance of steatosis in HIV-HCV coinfection remains controversial.

Cited by 42 publications

References 43 publications

Hepatic steatosis in patients coinfected with human immunodeficiency virus/hepatitis C virus: A meta-analysis of the risk factors

Hepatic steatosis in patients coinfected with human immunodeficiency virus/hepatitis C virus: A meta-analysis of the risk factors

Hepatitis C Virus Infection and Coinfection With Human Immunodeficiency Virus

Hepatic steatosis and steatohepatitis in human immunodeficiency virus/hepatitis C virus-coinfected patients

Contact Info

Product

Resources

About